The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes.
THURSDAY, Dec. 26, -- The U.S. Food and Drug Administration announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy, director of the FDA's Office of Generic
“Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Dec. 23, 2024. “Today's approval underscores the FDA's continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version oflevels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2
The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors.should not use liraglutide, nor should those who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2.Learn to better control your glucose levels by preventing blood sugar swings. Beware of caffeine, spices, exercise, sleep, alcohol, and stress as they impact blood sugar levels and increase diabetes complications.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Generic Version of Victoza Amid U.S. Drug ShortageThe Food and Drug Administration has approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes drug Victoza, which has been facing a shortage in the United States. The FDA prioritizes the review of generic alternatives for drugs in short supply. Generic drugs typically offer more affordable treatment options for patients.
Read more »
FDA Approves Generic Versions of Victoza and Byetta to Address Diabetes Medication ShortagesThe U.S. Food and Drug Administration (FDA) has approved two generic versions of popular diabetes medications, Victoza (liraglutide) and Byetta (exenatide), aiming to improve access to these essential treatments amid ongoing shortages.
Read more »
FDA Approves Hikma's Generic Version of Victoza, Expanding Treatment Options for DiabetesThe US Food and Drug Administration has approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes drug, Victoza. This approval opens the door for another generic option competing with Teva Pharmaceuticals' authorized generic in the US market. The FDA emphasizes that generic drugs offer more affordable treatment choices for patients.
Read more »
FDA Cracks Down on Unapproved GLP-1 Drug SalesThe FDA issued warning letters to five companies selling unapproved versions of popular diabetes and weight-loss drugs marketed as 'research use only'.
Read more »
FDA Approves First Allogeneic MSC Therapy for Steroid-Refractory Acute Graft-vs-Host Disease in ChildrenRyoncil, a mesenchymal stromal cell therapy derived from bone marrow, has received FDA approval for the treatment of steroid-refractory acute graft-vs-host disease (SR-aGVHD) in children aged 2 months or older. The approval marks a significant advancement in cell-based therapies for life-threatening diseases. In a phase 3 study, Ryoncil demonstrated effectiveness in inducing responses in children with SR-aGVHD.
Read more »
FDA approves first-ever medication for obstructive sleep apneaJustin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »